<DOC>
	<DOCNO>NCT02084238</DOCNO>
	<brief_summary>This clinical study test efficacy safety low dose IL-2 treatment Systemic lupus erythematosus .</brief_summary>
	<brief_title>Low-dose IL-2 ( Interleukin-2 ) Treatment SLE</brief_title>
	<detailed_description>Systemic lupus erythematosus ( SLE ) chronic autoimmune syndrome affect various organ . While available therapy , corticosteroid immunosuppressive agent improve outcome patient , remain significant unmet need safe effective treatment . Dysfunction regulatory T ( Treg ) cell detect diverse autoimmune disease , promote interleukin-2 ( IL-2 ) . We hypothesize low-dose IL-2 could novel therapy active SLE patient . This single center , uncontrolled , open-label study assess efficacy/safety low dose IL-2 plus standard therapy active SLE . Methods : Each SLE patient ( n=40 ) Scores &gt; =8 Safety Estrogens Lupus Erythematosus National Assessment ( AELENA ) version SLE Disease Activity Index ( SLEDAI ) refractory relaps glucocorticoid therapy receive low-dose IL-2 ( 1 million unit every day subcutaneously ( HrIL-2 1X 106 , ip , Qod ) period 14 day . After 14-day rest , another cycle start ) 3-6 cycle accord situation disease . The end point safety clinical immunologic response . Expected Results : This trail define low-dose IL-2 plus standard therapy efficacy safety active lupus patient , could relevant amelioration abnormity T help cell SLE patient .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Meet American College Rheumatology criterion diagnosis SLE . Under standard treatment ( ≥ 2 month ) time inclusion Background treatment fail control flare permit prednisone taper With least one follow manifestation : thrombocytopenia , diseaseassociated rash , mouth ulcer , noninfectious type fever , active vasculitis , renal disorder ( proteinuria &gt; 0.5g/day ) , neuropsychiatric SLE . Positive least one follow laboratory test : ANA &gt; 1:160 , antidsDNA , immunoglobulin &gt; 20g/L , decrease C3 C4 , leukopenia &lt; 3×10^9/L , thrombocytopenia &lt; 100×10^9/L ; SLE disease activity index ( SLEDAI ) ≥ 8 . Negative HIV test . Negative hepatitis B C virus . Written inform consent form . Sever chronic liver , kidney , lung heart dysfunction ; ( heart failure ( ≥ grade III NYHA ) , hepatic insufficiency ( transaminases &gt; 3N ) ) Serious infection bacteremia , sepsis ; Cancer history cancer cure less five year ( except situ carcinoma cervix Basocellular carcinoma ) ; Highdose steroid pulse therapy ( &gt; 1.5mg/kg ) IV bolus corticosteroid last 2 month . History administration rituximab biologics ; Purified protein derivative ( tuberculin ) &gt; 10mm Mental disorder chronic illness drugabuse could interfere ability comply protocol give information ; Inability comply IL2 treatment regimen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>SLE , IL-2</keyword>
</DOC>